FDA grants second Orphan Drug Designation to VS-01
Versantis successfully completes Phase 1b study and announces positive trial results
Agefi covers the U.S. FDA grant of Versantis latest Orphan Drug Designation
S&P Global Market Intelligence reports VS-01 Phase 1b data and speak about new ways to treat liver diseases.
Versantis selected among the Top25 best Scale-up companies in Switzerland
For the 5th year in a raw, Versantis ranks among Top100 best Swiss startups and was elected #2 BEST BIOTECH !
HOMEABOUT USDISEASE AREASPRODUCTSNEWSCAREERS
Versantis AGTechnoparkstrasse 1CH-8005 ZurichSwitzerland
Copyright © 2021Versantis AG